Weight loss injections Philadelphia: Difference between revisions

Weight loss injections Philadelphia (view source)

696 bytes removed , 30 June

5,477

edits

@@ Line 68: / Line 68: @@
 </div>
-'''Important note on retatrutide:''' The correct spelling is '''[[retatrutide]]''', not “ritatrutide.” Retatrutide is a triple hormone receptor agonist targeting [[GIP]], [[GLP-1]], and glucagon receptors. As of 2026, Lilly describes retatrutide as an investigational molecule legally available only to participants in Lilly clinical trials.{{cite web|url=https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html|title=Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial|publisher=Eli Lilly and Company|date=May 21, 2026|accessdate=June 30, 2026}} W8MD can educate patients about emerging obesity treatments and may consider future options when they become legally available, FDA-approved, medically appropriate, and safely accessible. Patients should avoid research peptides or unapproved GLP-1 products marketed online.
+'''Important note on retatrutide:''' The correct spelling is '''[[retatrutide]]''', not “ritatrutide.” Retatrutide is a triple hormone receptor agonist targeting [[GIP]], [[GLP-1]], and glucagon receptors and is considered investigational / experimental as of June, 2026.
 ==Why W8MD is a natural choice for weight loss==